MCMedicalCodingSoftware
Free trial
XW03398

XW03398 — Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Inebilizumab in Periph Vein, Perc, New Tech 8

How XW03398 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 3Body partThe specific site
  5. 3ApproachHow the site was reached
  6. 9DeviceWhat was left in place, if anything
  7. 8QualifierA further distinction where one applies

Codes near XW03398

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW03368Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03372Introduction of Inactivated Coagulation Factor Xa into Peripheral Vein, Percutaneous Approach, New Technology Group 2
  • XW03377Introduction of Trilaciclib into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03378Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03387Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW03388Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0338AIntroduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW03396Introduction of Ceftolozane/Tazobactam Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6
  • XW03398Introduction of Inebilizumab-cdon into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0339AIntroduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033A7Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033B3Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3
  • XW033B7Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033BAIntroduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033C7Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033CAIntroduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033DAIntroduction of Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension into Peripheral Vein, Percutaneous Approach, New Technology Group 10
ICD-10-PCSFY2026